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Abstract
Background: α-Synuclein is a small soluble protein, whose physiological function in the healthy brain is poorly
understood. Intracellular inclusions of α-synuclein, referred to as Lewy bodies (LBs), are pathological hallmarks of α-
synucleinopathies, such as Parkinson’s disease (PD) or dementia with Lewy bodies (DLB).
Main body: Understanding of the molecular basis as well as the factors or conditions promoting α-synuclein
misfolding and aggregation is an important step towards the comprehension of pathological mechanism of α-
synucleinopathies and for the development of efficient therapeutic strategies. Based on the conversion and
aggregation mechanism of α-synuclein, novel diagnostic tests, such as protein misfolding seeded conversion assays,
e.g. the real-time quaking-induced conversion (RT-QuIC), had been developed. In diagnostics, α-synuclein RT-QuIC
exhibits a specificity between 82 and 100% while the sensitivity varies between 70 and 100% among different
laboratories. In addition, the α-synuclein RT-QuIC can be used to study the α-synuclein-seeding-characteristics of
different α-synucleinopathies and to differentiate between DLB and PD.
Conclusion: The variable diagnostic accuracy of current α-synuclein RT-QuIC occurs due to different protocols,
cohorts and material etc.. An impact of micro-environmental factors on the α-synuclein aggregation and conversion
process and the occurrence and detection of differential misfolded α-synuclein types or strains might underpin the
clinical heterogeneity of α-synucleinopathies.
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Background
α-Synucleinopathies, such as Parkinson’s disease (PD),
dementia with Lewy bodies (DLB) or multiple system at-
rophy (MSA), are a class of neurodegenerative diseases
characterized by the presence of misfolded, fibrillary α-
synuclein. In PD and DLB, the deposits of α-synuclein
(Lewy bodies, (LBs)) occur intracellular within neurons,
while MSA patients show oligodendroglial cytoplasmic
inclusions (GCI), called Papp-Lantos bodies, rather than
neuronal aggregates.
Even though the cellular distribution of aggregated α-
synuclein is different, there is a significant pathological
overlap. In both diseases, neurodegeneration is associated
with the LBs and GCI burden, as well as the increase of
soluble α-synuclein in substantia nigra and striatum [1].
In addition, there is an apparent overlap in degeneration
of the dopaminergic nigrostriatal system in PD and MSA.
The folding process of a protein (e.g. α-synuclein) occurs
in dependence on its energetic landscape, defined by the
thermodynamic constrictions that force it to assume the
conformation of the lowest free energy. Whereas protein
folding is regulated mostly by chaperones [2, 3], a class of
proteins called intrinsically disordered proteins (IDPs,
such as α-synuclein), which owns a low complexity region
that may adopt an alternative, β-sheets enriched conform-
ation [4–7], show poor binding features to chaperones [8–
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11]. IDPs may form fibrils and plaques [12], characterized
by a β-sheet conformation with β-strands perpendicular
to the length of the fibril, favoured by an exclusion of
water from the inner core of the fibril and hydrophobic in-
teractions. The summation of all forces enables the mis-
folded protein to cross its metastable intermediate stages
and lean toward the minimal energy level of the misfolded
amyloid [13]. Whereas equilibrium among the native and
the intermediate stages (which may be populated by oligo-
mers) is possible, the formation of amyloids represents an
irreversible process. Previous studies indicate that the mis-
folding and subsequent conversion of one or more pro-
teins into a pathogenic variant may contribute to the
onset of neurodegenerative diseases, retracing the protein-
only hypothesis originally formulated for the prion protein
[14–17]. According to this view, the propagation of mis-
folded proteins requires the formation of a homotypic
complex between the two conformers of a protein [17],
which leads to the conversion of the native form into the
pathogenic form. The novel β-sheet-enriched molecule
may act as a seed, contacting other native molecules (typ-
ically referred as substrate) and imposing the conversion
into β-sheets, establishing a positive feedback that eventu-
ally causes the aggregation into plaques and fibrils.
In this review we focus on α-synuclein, a protein
whose intracellular aggregates are hallmarks in α-
synucleinopathies. At first, we discuss the potential
prion-like conversion behaviour of α-synuclein. After-
wards, we summarize the micro-environmental factors
that may affect the α-synuclein aggregation process and
their impact on the diagnostic performance of major
techniques based on the seed-mediated conversion of
misfolded species of α-synuclein. At last, we review the
state of the art about the existence and the impact of dif-
ferent synuclein strains that may contribute to different
clinical features in α-synucleinopathies.
Main text
Conversion and transmission of misfolded α-synuclein
Being a natively unfolded protein [18], α-synuclein ag-
gregation is ruled by thermodynamics [19]. The first
event in the assembly of α-synuclein is supposed to be
dimerization [20], leading in turn to the generation of
aggregation-competent oligomers, encompassing a wide
variety of structures [21], and possessing their own kin-
etics of fibrillization and toxicity [22].
The conversion behaviour of α-synuclein, described as
“prion-like”, has been reported by evidences of graft-to-
host spreading of α-synuclein aggregates [23–25]. Aggre-
gated α-synuclein can be transmitted from neuron to
neuron [26] either after neuronal death or by exocytosis-
mediated pathways [26], while the uptake may occur be
endocytic pathways [27], substantiating the neuron-to-
neuron transmission and the predictable spreading
observed in some forms of α-synucleinopathies. Recently,
α-synuclein was shown to interact with high density lipo-
proteins [28] and the presence of α-synuclein, both in its
native and misfolded conformation, was found in extracel-
lular vesicles as well [29, 30], suggesting a potential novel
route for the spreading of the pathology. Moreover, α-
synuclein transmission along axonal connections was
demonstrated ex vivo and in vivo in various animal
models.
Luk and co-workers demonstrated that fibrillary α-
synuclein is able to trigger the conversion of monomeric
α-synuclein into aggregates closely reminiscent of LBs
and neurites in a cell model overexpressing α-synuclein
[31]. Fibrillary α-synuclein was further found to be
transported anterogradely through the axon and taken
up by the next neuron in mouse embryonic cultures
[32], while in vivo studies conducted with rats showed
the trans-neuronal spreading of fibrils from the olfactory
bulb toward other non-olfactory regions [33]. The trans-
port of fibrillary α-synuclein forms were shown to follow
an anterograde pathway through the axon and passaged
to the next neuron in mouse embryonic cultures. More-
over, in vivo studies conducted in rats demonstrated that
α-synuclein fibrils spread from the olfactory bulb toward
other non-olfactory regions [33]. Others showed that α-
synuclein aggregates were inoculated in the medulla
oblongata of rats, and the caudo-rostral spreading was
followed by showing fibers and neuronal abnormalities
in the rostral mesencephalon and in prosencephalic re-
gions after 18 weeks [34]. Lastly, PD pathology was suc-
cessfully passaged to non-human primates by
administration of human PD-derived LBs.
The spreading of α-synuclein through different routes
may highlight the differential affinity of different cell
types toward α-synuclein binding and internalization, as
the cellular milieu differs among populations of cells de-
rived from different developmental lineages. Thus, the
cellular environment may play an instructive role for the
spreading of misfolded α-synuclein, affecting first highly
vulnerable cell lineages.
In the next section, we will address the environmental
factors that may affect the aggregation of α-synuclein, its
seeding ability and thus the modes of spreading through
various routes.
Micro-environmental factors affecting the α-synuclein
aggregation
A plethora of environmental factors have been found to
affect protein misfolding and aggregation [35]. Physical
factors, such as molecular crowding and temperature, may
affect protein aggregation by enhancing the entropy of the
system. Similarly, chemical factors such as pH variations
or the presence of other proteins or biomolecules, such as
nucleic acids, phospholipids and proteoglycans, may affect
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the aggregation process. Moreover, post-translational
modifications (PTMs) may also interfere with the aggrega-
tion process by affecting the surface charge or the top-
ology of the protein. The effect of these conditions on α-
synuclein aggregation is summarized in Table 1.
Additional, often overlooked factors in PD patients,
which influence the misfolding and aggregation features
of α-synuclein, are missense point mutations in the α-
synuclein gene (SNCA) (e.g. A53T, A53E) as well as the
potential increase of α-synuclein expression levels, in-
duced by duplications or triplications of SNCA. The
genetic A53T missense mutation causes conformational
changes in α-synuclein with structural alterations of the
β-sheet structures, thermodynamically more stable in
aqueous solutions, exhibiting a significant influence on
the aggregation process [36]. Experimentally, the inte-
gration of a genetic PD associated point mutation in re-
combinant α-synuclein substrate would accelerate the
seeding response of oligomeric α-synuclein in seeded ag-
gregation assays. However, it may also promote the self-
aggregation of the substrate and the generation of false-
positives, as we discuss in a dedicated section below.
PH and metal ions
Low pH can be viewed as a factor promoting protein ag-
gregation by increasing the net surface charge and hence
enhance side chain repulsion, allowing the exposure of the
aggregation-prone hydrophobic core [37]. Indeed, the
growth of α-synuclein fibrils was shown to be impaired at
neutral pH while it was magnified at mildly acidic pH
values (5.8) [38], indicating a critical role of the chemical
conditions of the micro-environment surrounding the
nascent fibril. Similarly, changes in the environmental pH
have been found to affect the amyloidogenic properties of
β2-microglobulin, a protein expressed in nucleated plas-
matic cells whose aggregates are found in dialysis-related
amyloidosis at acidic pH levels [39]. Metal ions have been
shown to behave similarly to pH variations by neutralizing
charge repulsion and thus imposing a more compact and
aggregation-prone structure to α-synuclein [40]. The
Table 1 Factors affecting α-synuclein aggregation. The table summarizes the effects of various chemical, physical and biological
agents on α-synuclein aggregation. Effect is either defined as enhancing when promotes the aggregation or quenching when it
slows down the aggregation. The rationale for the effect is listed in the table as well.
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efficiency in inducing the folding increases with the charge
density, reaching a maximum at approximately 2.5 Å− 3.
Therefore, small polyvalent cations are more effective in
triggering the structural changes when compared to large
monovalent cations. Polyvalent cations may also create
bridges between carboxylate residues, further increasing
the transition to a partially folded structure.
Polyamines
Polyamines are a group of physiological polycations in-
volved in several biological functions, spanning from
DNA replication to protein synthesis [41]. They present
multivalent cations separated by aliphatic hydrocarbon
chains, through which they can interact with natively
unfolded proteins both via electrostatic and hydrophobic
interactions [42]. High order polyamines, such as putres-
cine, spermine and spermidine, have been found to be
involved in cellular toxicity during the development of
PD [43]. Polyamines have been shown to enhance α-
synuclein aggregation in a manner proportional to the
cation charge and the length of the aliphatic chains sep-
arating the amino groups [44]. Therefore, the most po-
tent among them is spermine, which owns four cationic
groups separated by three hydrocarbon chains. An in-
depth study of the conformational change of α-synuclein
induced by spermine has been carried out using force
spectroscopy coupled with atomic force microscopy [45].
Here, the C-terminal alanine of α-synuclein has been
substituted with a cysteine, thus allowing the covalent
binding to the tip of the atomic force microscope and to
the mica surface. With this experimental design, re-
searchers were able to show that α-synuclein assembly is
potently enhanced by polyamines at the very first steps
of the process, indicating that even the first steps of the
aggregation (i.e., dimerization) may show heterogeneity.
Proteoglycans
Proteoglycans are glycoproteins containing sulphated
glycosaminoglycan chains (GAG). They are expressed in
the outer leaflet of the cellular membrane, where they
are involved in the internalization of amyloids [46, 47].
Due to the presence of both a negatively charged moiety
(sulphated groups) and a positively charged amino acids,
their binding to amyloids has been reported to be both
detrimental and protective [48, 49] and, consequently,
different types of proteoglycans may display opposite ef-
fects towards protein aggregation.
Agrin, a neuronal heparin sulphate proteoglycan, has
been found to localize with all Alzheimer’s lesions and
has been proposed to contribute to the formation of LBs
and neurites. Binding studies and circular dichroism
analyses have shown that agrin increases the insolubility
of α-synuclein in vitro and enhances the formation of
the fibrils [50]. Since agrin contains two potential sites
for the attachment of GAG moieties, a subset of glyco-
sylated agrins may exist in the brain, each owing differ-
ent functions and distinct affinities for α-synuclein.
Nucleic acids
Nucleic acids have been reported in association to amyl-
oid plaques and tangles in protein misfolding diseases.
Since they own high binding affinity for amyloids, they
have been supposed to act as a scaffold to promote pro-
tein aggregation [51]. Due to the net positive surface
charge of amyloids, the favoured electrostatic interac-
tions of the peptide chain and phosphate groups of nu-
cleic acids promote the aggregation. This interaction
may further increase the local concentration of amyloid
proteins, supporting the aggregation through interaction
of the exposed hydrophobic domains with neighbour
proteins [52, 53].
Nucleic acids have been indeed shown to enhance prion
protein, superoxide dismutase-1, amyloid-β and tau aggre-
gation [54]. α-Synuclein has been shown to possess differ-
ential binding affinity towards different conformations of
nucleic acids. Hegde and co-workers [55] studied the bind-
ing of α-synuclein with different topologies of DNA by cir-
cular dichroism spectroscopy, intrinsic fluorescence and
binding to fluorescent reporter for amyloids such as
thioflavin-T (Th-T) and ANS. Single-stranded circular
DNA was shown to induce the formation of an α-helix
within α-synuclein, inhibiting the aggregation, whereas
small oligonucleotides and linear double-stranded DNA
caused a partial folding that leans towards the aggregated
state. Moreover, GC-rich DNA was shown to induce ag-
gregation in a more efficient way compared to AT-rich
DNA.
Poly-ADP ribose (PAR)
Poly-ADP ribose (PAR) is a non-coding polynucleotide
produced by the PAR polymerase upon DNA damage
[56], mediating a form of necrosis termed parthanathos
(from the ancient Greek embodiment of death, Tha-
nathos), which represents a major cell death pathway in
neurodegenerative diseases [57]. Outside of triggering cell
death through the mitochondrial release of the apoptosis
initiating factor [58], PAR was shown to accumulate next
to the DNA breakage foci upon external or internal stress-
ful events, where it initiates liquid remixing to achieve
intracellular, membrane-less compartmentalization [57].
Such newly formed organelles act as a seed for the assem-
bly of IDPs, which are in turn excluded from damaged
areas to allow DNA reparation and promote genome sta-
bility. Depletion of PARP by CRISPR-Cas9 (Clustered
Regularly Interspaced Short Palindromic Repeats and
CRISPR-associated protein 9) in neuronal cultures was
shown to prevent cell death mediated by α-synuclein pre-
formed fibrils (PFFs) and to inhibit their propagation to
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neighbouring cells [59]. Indeed, α-synuclein PFFs were
shown to trigger PARP activation via production of nitric
oxide and subsequent DNA damage. In turn, PAR overex-
pression caused enhanced α-synuclein aggregation
through liquid remixing, producing α-synuclein strains
that were more compact and hence more toxic. These re-
sults were replicated in vivo, showing that whereas intras-
triatal injection of α-synuclein PFFs in wild type recipient
mice caused increased PAR levels and loss of dopamin-
ergic neurons within 6months, injection in PARP-1
knockout recipient mice failed to trigger neuronal loss.
Fatty acids
Lipid bilayers have been indicated as a factor that may
reduce the activation energy barrier required for proteins
to accommodate into the amyloid state [60], by interact-
ing with the positively charged surface of amyloidogenic
proteins and thus increase the local concentration and
unmask the hydrophobic core of the proteins. Many
neurodegenerative related proteins, including α-
synuclein [61], have been shown to insert to lipid bilay-
ers [60] and have been suggested to act as anchor for fi-
brils assembly. Indeed, the interaction with biological
membranes may increase the local concentration of the
unfolded protein, thus increasing the probability of ex-
posing the hydrophobic core that drives protein aggrega-
tion. Perrin and co-workers [62] analyzed the exposure
of α-synuclein to different fatty acids. Roughly two thirds
of α-synuclein forms a vesicle binding domain, which
was proposed to serve a role in synaptic physiology [63].
Upon binding to vesicles, α-synuclein is reshaped into
an α-helix containing conformation, which was shown
to be resistant to various disruption methods, such as
SDS, acidification and boiling. However, not every lipid
can trigger α-synuclein aggregation, as the length of the
acyl chain is critical for the aggregation. Only short and
saturated hydrocarbon chains [64] were shown to be
able to induce α-synuclein aggregation, whereas poly-
unsaturated fatty acids [65] form stable multimers with
α-synuclein. Therefore, it appears that α-synuclein ag-
gregation may either be enhanced or quenched accord-
ing to the kind of fatty acid it binds to. Lastly, the
physical properties of the membrane also affect the ag-
gregation, as it was shown that α-synuclein binding to
biological membranes is much stronger when it binds to
the fluid state compared to the gel phase [66].
Post-translational modifications (PTMs)
The interaction of α-synuclein with the micro-environment
is influenced by the presence of PTMs, which may change
the degree and the type of interaction, resulting either in
enhancing or quenching the kinetic of aggregation. Indeed,
the presence of phosphorylated and ubiquitinated α-
synuclein is a hallmark of LBs and neurites [67]. Although
the role of PTMs in synucleinopathies is more complex and
has been extensively reviewed elsewhere [68, 69], we briefly
summarized the most relevant PTMs in the process of α-
synuclein aggregation.
Clinical and functional studies [70–72] converge on
the observation that the dysregulation of glucose metab-
olism may be an important risk factor for the develop-
ment of α-synuclein related pathologies. Catabolic
processing of glucose generates advanced glycation end-
products (AGEs), reducing sugars that may covalently
bind to proteins, thus affecting their structure and func-
tion. By displaying a comprehensive approach involving
yeast models, human stem cells, flies and mice models,
and human tissues, Vicente Miranda and co-workers
[73] demonstrated by a wide variety of biochemical, bio-
physical imaging and electrophysiological techniques
that glycation of α-synuclein in its amino-terminal moi-
ety by AGEs exploits α-synuclein toxicity and aggrega-
tion, impairs motor ability and electrophysiological
properties. These effects appear to be mediated by the
disruption of the N-terminal binding to lipid mem-
branes, altering the trafficking and hindering the ubiqui-
tination, thus impairing the degradation through the
proteasomal pathway.
These evidences suggest that hyperglycemia may con-
tribute to the onset of synucleinopathies, substantiating
the role of diabetes as a risk factor for Parkinson’s disease.
Moreover, the association of AGEs with α-synuclein ag-
gregation corroborates the association between mutations
in genes coding for glyoxalase and deglycase enzymes,
such as DJ-1 and recessive forms of Parkinson’s disease.
Among the various phospho-sites involved in α-
synuclein aggregation, phosphorylation at residue Ser129
appears to be the most relevant in pathology and, there-
fore, the most studied [74]. However, data diverges in
identifying the role of this PTM in pathology, as it was
shown to be both protective and toxic [75] in different
systems.
In its physiological state, α-synuclein appears to be
constitutively N-terminal acetylated [76] at several ly-
sines residues. The presence of this PTM appears to
affect the binding to high curvature vesicles and to vesi-
cles owing low negative charge, whereas the binding to
highly negative charged structures appears to be un-
affected [77]. Overall, acetylation contributes to maintain
the equilibrium between monomeric-, soluble forms and
tetrameric-, membrane bound assemblies.
Another physiological PTM of α-synuclein is its C-
terminal truncation [78, 79], associated with the lyso-
somal pathway. Carboxyl-terminal truncated α-synuclein
has been estimated to constitute 10–25% of the LBs
[79]. Indeed, C-terminal truncation has been associated
with an increase in self-assembly properties of α-
synuclein [78].
Candelise et al. Translational Neurodegeneration             (2020) 9:5 Page 5 of 16
Nitration is another common PTM found in LBs [79].
Nitric oxide is produced upon oxidative stress, causing the
nitration of tyrosine residues. Nitration of tyrosine residues
in α-synuclein is supposed to hinder the formation of ag-
gregates [80], causing the formation of dityrosine bridges
that stabilizes low molecular weight oligomers.
When purified from LBs, α-synuclein appears to be
mono-ubiquitinated [81]. The addition of a single ubi-
quitin molecule is a signal for proteasome degradation,
whereas poly-ubiquitination triggers the degradation
through the lysosomal pathway [82, 83]. However, α-
synuclein may also be conjugated with the small ubiqui-
tin like modifier (SUMO) in a process termed SUMOyla-
tion [84]. The addition of this residue was shown to
have opposite effect to ubiquitination [85]. Whereas ubi-
quitination favours the degradation of α-synuclein,
SUMOylation was shown to inhibit synuclein ubiquitina-
tion, leading to an increase of the local concentration of
α-synuclein and therefore promoting the aggregation
process.
Lastly, the presence of other proteins may affect the
aggregation process. Although homotypic seeding is the
preferred form of aggregation, heterotypic cross-seeding
of α-synuclein with other natively unfolded proteins
(such as tau or PrPC [86, 87]) has been reported as well.
Physical factors that may impact amyloidogenesis are
ascribed to thermodynamic events. Temperature, con-
centration and the application of an external force may
increase the entropy of the system, hence increasing the
chances of triggering the aggregation.
The sum of biological and physical factors dramatically
impacts the experimental detection of the misfolding
and aggregation process. Whereas the presence of aggre-
gates has been classically studied by forcing the forma-
tion of fibrils in vitro [88, 89], the most recent
techniques take advantage of the prion-like mechanism
to seed the conversion, and thus reducing the time for
the detection of the aggregates. Indeed, the presence of a
single misfolded unit enhances dramatically the aggrega-
tion by the transmission (in vitro and in vivo) of its con-
formational information to natively folded neighbour
molecules, giving rise to self-propagating molecules. The
misfolding and prion-like conversion behaviour of one
or more proteins has been observed in a wide variety of
neurodegenerative diseases [8, 14, 15, 35]. Currently, the
conversion behaviour of misfolded proteins (e.g. α-
synuclein) is the basis for the development of a group of
methodologies analyzing the process of protein misfold-
ing in vitro.
Protein misfolding cyclic amplification assays
The importance of the self-assembly properties in the
onset of neurodegenerative diseases have led to the in-
vestigation of the kinetic of the aggregation. During the
onset of the pathology, this process is typically slow.
However, it can be mimicked in vitro and, under appro-
priate conditions, it may occur much faster than during
pathology. Independently from physical and chemical
factors, which may influence the fibrillization process,
the presence of a molecule which is prone to aggregation
and can act as a nucleus or seed for the fibrillization, al-
lows the reduction of the lag phase and avoids the pos-
sible denaturation of the monomers during the reaction
[90, 91]. The growth of the α-synuclein fibrils follows a
sigmoidal curve (Fig. 1). It displays a lag phase, during
which the nucleation process subsequently, the exponen-
tial phase indicates the elongation of the fibrils, before a
plateau phase can be observed once the monomers have
been converted into β-sheet enriched species, which sat-
urates the signal (Fig. 1). The seeded conversion assays
have been applied for the detection of misfolded proteins
for the diagnosis of prion diseases. In this frame, a fun-
damental innovation was the development of the protein
misfolding cyclic amplification (PMCA) [93]. The aim of
the study was to reproduce the conversion of PrP
in vitro by seeding the reaction with minute amounts of
the misfolded form of PrP. To this end, the aggregation
of PrPC from healthy brain homogenates was triggered
by the addition of brain homogenates from scrapie-
infected hamsters in a cyclic reaction, consisting in cy-
cles of incubation and sonication. The former step al-
lows the seed to contact and convert its native
counterpart and to form growing oligomers, whilst the
latter step breaks longer fibrils to increase the number
of smaller seeding-competent aggregates, hastening the
conversion process. The end-product was shown to be
proteinase K (PK)-resistant by Western blotting. The
PMCA was further automated [94–96] to make it suit-
able for the analyses of biological fluids (blood, urine or
the cerebrospinal fluid (CSF) [97, 98]) and, recently, its
application was expanded to the detection in biofluids of
other neurodegenerative-related molecules, such as the
CSF from patients with α-synucleinopathies [99].
To overcome the inherent complications of the PMCA,
such as poor reproducibility, the time-consuming need of
PK-resistant PrPres detection via Western blotting, the
careful handling of the infectious end-product and the
lack of consistency with different prion strains [100],
other in vitro, cell-free, amplification assays for misfolded
proteins have been developed. The substitution of sonic-
ation by shaking [101, 102] represented a major advance-
ment. Indeed, by increasing the air-water interface,
shaking is thought to cause the unfolding of PrP and
to enhance the fragmentation into oligomers, thus
favouring the seed-substrate interaction [103]. The assay,
termed real-time quaking-induced conversion (RT-
QuIC), was further refined by the real-time screening of
the course of the reaction by adding the fluorescent dye
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Th-T (Fig. 1). In this assay, small amounts of misfolded
PrPSc seeds recruit single recombinant PrPC substrate
molecules and induce their conversion by integrating
them into a growing amyloid aggregate concomitant with
a conformational change of the substrate into a seeding-
competent state (Fig. 1) [92, 101]. The RT-QuIC consists
of cycles of incubation steps, where the size of the amyl-
oid product, PrPRes, increases exponentially and vigorous
shaking steps, which fragment PrPSc aggregates into
smaller seeds promoting the conversion (Fig. 1). The
PrPSc-seeded conversion reaction product, PrPRes, is
enriched in β-sheet secondary structures. The generation
of these β-sheets can be monitored in real-time by using a
temperature-controlled shaking fluorescence plate
reader and by adding a fluorescence dye, Th-T, in the re-
action mix.
Development of the α-synuclein RT-QuIC
In contrast to previous diagnostic assays (colorimetric
ELISA, Western blot etc.) for analysis of surrogate bio-
marker proteins (such as tau and 14–3-3), whose regu-
lation in CSF is based on neurodegeneration process in
brain tissue, RT-QuIC analysis allows an ultrasensitive
(femtomolar) detection of pathogenic proteins, exhibit-
ing a specificity close to 100% [92]. Recently, the RT-
QuIC was successfully applied for the template-induced
seeding conversion of α-synuclein, which enables the
detection of α-synuclein misfolded species reported by
different groups, employing different protocols in
regards of the physical conditions (e.g., shaking,
temperature, chaotropic agents) and chemical micro-
environment (e.g., pH, ionic strength, presence of
detergents).
Fig. 1 Diagram of the potential seeding-conversion mechanism of α-synuclein during the RT-QuIC. The seed (in red) triggers the aggregation of
monomeric α-synuclein (substrate, in green). The conversion causes the conformational modification into misfolded oligomers (blue) that
elongate into fibrils. After the detection of fibrils, a quaking event breaks the longer fibrils into shorter, reactive oligomers, which further seed the
conversion of monomeric α-synuclein (modified from [92]). The classical shape of the kinetic curve is shown within the aggregation process
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Fairfoul and colleagues detected by RT-QuIC the
seeding activity of misfolded α-synuclein derived from
both CSF and brain homogenates [104]. The reaction
was promoted by the addition of zirconia/silica beads to
achieve sensitivity of 95% and specificity of 92–100%, re-
spectively for DLB and PD diagnosis. Further, the au-
thors reported the detection of prodromal stages of
DLB, showing positive RT-QuIC results from cases af-
fected by rapid eye movement (REM) behaviour sleep
disorder, a hallmark of the prodromal stage of DLB. A
biochemical and biophysical characterization of the RT-
QuIC products from RT-QuIC reactions seeded with
DLB derived brain homogenates was conducted by Sano
and co-workers [105]. They obtained an accuracy of
100% specificity, 92% sensitivity for DLB and 95% sensi-
tivity for PD. The tested α-synuclein was either wild-
type, phosphorylated at residue 129 (pSer129) (com-
monly observed in patients with α-synucleinopathies) or
non-phosphorylable α-synuclein, containing a point mu-
tation (S129A). The seeding activity of S129A oligomers
was higher than that of wild-type oligomers regardless of
phosphorylation state. In a second RT-QuIC passage
(that is, using the RT-QuIC products as seed for a sec-
ond run), the highest seeding activity was observed when
oligomeric species were produced by S129A α-synuclein
in the presence of ATP and casein kinase (CK, that
phosphorylates α-synuclein at residue S129), whereas
wild-type α-synuclein in presence of either CK alone or
both CK and ATP, showed a lower aggregation signal.
These results point toward a possible protective effect of
pSer129, which may generate inert fibrils faster hinder-
ing the aggregation. However, the presence of ATP alone
was not investigated, as the presence of the nucleoside
may promote the aggregation regardless the primary se-
quence of the substrate.
Another group, Groveman et al. [106], reported an ag-
gregation of monomeric α-synuclein in reactions seeded
with CSF or brain homogenate from DLB and PD pa-
tients. 100% of specificity and 93% of sensitivity for α-
synucleinopathies (DLB and PD grouped together) was
obtained by using as substrate α-synuclein owing a point
mutation, K23Q, which confers a lower propensity to
self-aggregation.
Manne and co-workers [107] achieved α-synuclein ag-
gregation in the RT-QuIC by using as seed either CSF or
brain homogenates in combination of SDS and chaotro-
pic agents (zirconia/silica beads, similarly to Fairfoul’s
protocol) to enhance the conversion of monomeric α-
synuclein in RT-QuIC reactions, seeded with DLB and
PD brain homogenates, with PD CSF and with a subset
of progressive supranuclear palsy (PSP, a neurodegenera-
tive disease characterized by tau aggregates). Moreover,
researchers induced α-synuclein aggregation in reactions
seeded with protein extracts from a microglial cell
culture infected with pre-formed α-synuclein fibrils. The
observations indicate that the seed for the RT-QuIC can
also derive from a cell system.
Candelise and co-workers recently published a study
in which positive RT-QuIC signals could be obtained
specifically from DLB-brain seeded reactions [108]. In
order to avoid possible contamination from macromole-
cules that may skew the aggregation process, a new pre-
analytical fractionation protocol for brain homogenates
was established. Under avoidance of bead addition (arti-
ficial inducer of α-synuclein aggregation), the α-
synuclein RT-QuIC was successfully applied for the spe-
cific discrimination of DLB patients (positive response)
from PD (negative response on control level). Biochem-
ical analyzes confirmed the generation of a fibrillary,
proteinase K (PK)-resistant seeding competent α-
synuclein species only in DLB-brain seeded RT-QuIC re-
actions, pointing toward the existence of different α-
synuclein strains in DLB and PD cases. Importantly, the
RT-QuIC results were neither influenced by the brain
region analyzed nor by the co-pathology or other epi-
demiological factors, such as age, sex, severity of the dis-
ease, and age of onset [108]. Controversial findings
regarding a lack of α-synuclein seeding in PD patients
might be explained by the addition of beads and the pre-
analytical treatment (fractionation protocol) [104, 106].
Further factors, such as the kind of purification method
of recombinant α-synuclein substrate or the presence of
additional compounds (e.g. SDS, metals) may also have
an impact on the seeding response.
The standard purification protocol includes a HPLC/
FPLC step [105]. This step is particularly important for
removing nucleic acids, as the presence of DNA/RNA
influences the aggregation kinetics. Moreover, α-
synuclein is prone to bind metal ions, specially copper
(e.g. His50) which accelerate its aggregation. Therefore,
standard protocols to purify recombinant α-synuclein
from E. coli include chelator compounds, commonly
EDTA, in the purification buffers. Finally, there are dif-
ferent purified α-synuclein species generated during the
purification process (oligomeric and monomeric). Specif-
ically the oligomeric species (removable by an additional
filtration step) is prone to aggregation which results in a
higher seeding propensity in the RT-QuIC as well as in
self-aggregation of the substrate.
Garrido and co-workers [109] applied the protocol ori-
ginally proposed by Fairfoul [104] and used in other
studies [110, 111] to assess the presence of α-synuclein
aggregation competent species in the CSF derived from
α-synucleinopathies patients carrying a genetic PD mu-
tation in the gene coding for leucine -rich repeat kinase
2 (LRRK2). By testing 10 idiopathic PD cases, they found
a specificity of 90% and a specificity of 80%. Samples de-
rived from LRRK-PD subjects showed a specificity of
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40% (6 out of 15), while 3 of 16 (18.8%) of non-
manifesting LRRK2 carriers showed a positive RT-QuIC
signal response.
Finally, De Luca et al [112] performed a cross-sectional
observational study, carried out by seeding the RT-QuIC
reaction with brain material derived from cases affected
by PSP, frontotemporal dementia (FTD) and corticobasal
degeneration (CBD), PD and MSA. Serial steps of high
speed centrifugation were conducted to enrich the
seeding-competent α-synuclein species and diluted to a
working concentration of 10− 3. Moreover, they obtained
47 samples of olfactory mucosa (OM) from PD, MSA,
PSP and CBD cases. Researchers were able to detect seed-
ing activity from reactions seeded with brain homogenates
from PD and MSA patients, while no signal could be de-
tected from reactions seeded with PSP, CBD, FTD or con-
trols. When testing the OM samples, they detected
seeding activity in 10 out of 18 PD cases (55.5% sensitivity)
and in 9 out of 11 MSA cases (81.8% sensitivity). Thus,
the overall sensitivity of PD and MSA grouped cases was
65.5%, whereas negative controls from PSP and CBD gave
positive results respectively in 1 out of 6 and 2 out of 12
cases (overall specificity 84.3%). Both brain -and OM
seeded reactions showed a lag phase of approximately 40
h. The group further analyzed the RT-QuIC fibrils
by transmission electron microscopy, considering the
length, the shape and the number of fibrils in the RT-
QuIC end-products seeded with OM derived material.
They found a statistically significant difference between
PD derived fibrils and MSA derived fibrils, with the
former owing a shorter over-twist distance compared to
the latter. These fibrils were different from those derived
from the positive RT-QuIC assays seeded with PSP and
CBD material (respectively, PSP derived were longer than
MSA, whilst CBD were the shortest produced during the
RT-QuIC).
Thus, outside of the great improvement in the usage
of a seed derived from a source other than CSF (which
dramatically improves the well-being of a patient, com-
pared to the painful procedure of the lumbar puncture),
they also produced evidences of a difference in the seed-
ing activity of PD derived α-synuclein compared to MSA
derived α-synuclein, indicating a putative strain differ-
ence between both pathologies, in line with previous
studies reporting putative strain differences among synu-
cleinopathies [113–115].
Even though several studies (mentioned before) ob-
served a seeding activity of pathogenic α-synuclein, their
protocols were different for chemical and physical condi-
tions and, more importantly, for the starting seed and
the kind of purified α-synuclein substrate used for the
reactions. Most of the groups used human full length α-
synuclein from different companies, and different kinds
of beads were added in the reaction to accelerate the
conversion. In addition, the purified α-synuclein sub-
strate can already be partially aggregated (preformed fi-
brils) or genetic (PD mutations were included in the
substrate sequence), enhancing the seeding propensity in
the RT-QuIC reaction. The presence of the positively
charged histidine moiety (required for the purification),
may further promote the self-aggregation properties of
α-synuclein. Moreover, the addition of further com-
pounds such as SDS can change the seeding kinetic and
the sensitivity of the α-synuclein RT-QuIC. Differences
among protocols and their clinical accuracy (specificity,
sensitivity) are summarized in table form (Table 2).
It is therefore apparent that multiple experimental set-
tings may be exploited for the detection of α-synuclein
seeding activity in the RT-QuIC. A different “micro-envir-
onment” in the reactions, different physical conditions for
the aggregation, a different source for the seed, the usage
of different substrates or more probably the combinations
of these factors, may lead to the detection of α-synuclein
seeding activity from different α-synucleinopathies.
Upon protein aggregation, a population of conform-
ational variants could be produced, which compete for
the same source (i.e., the native version of the misfolded
protein) as a function of the environmental conditions.
The different conformations that arise from the same
misfolded protein have been referred as strains.
Evidences for the existence of different α-synuclein
strains
The term “strain” was first introduced to discriminate the
pathological phenotypes associated with the intracerebral
inoculation of the prion protein in goats [116–118]. Upon
misfolding, a single unit may accommodate into different
conformations, giving rise to different pathological frames.
Strains hence refer to separate conformations of the same
protein. Since their inception in the prion field, a variety
of strains has been characterized [119, 120]. The conform-
ation may be altered by the genetic background of the
host and the source of the pathogenic protein, as well as
post-translational modifications, chemical and physical
conditions of the micro-environment in which the process
takes place, leading to a heterogeneous strain population.
Different transmission properties of α-synuclein species
in vitro and in vivo
The transmissibility of misfolded α-synuclein (either from
brain homogenates of a donor or recombinantly produced
fibrils) indicates a prion-like seeding and conversion activ-
ity. Relevant for a successful transmission of α-synuclein
fibrils in rodent brains inducing a Parkinson-like path-
ology is an overexpression of α-synuclein which serves as
a substrate for the inoculated α-synuclein seed [121].
The transmissibility of MSA derived α-synuclein was
demonstrated by the injection of brain homogenates
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from MSA patients into hemizygous TgM83+/− mice
[111], which possess the mutation A53T, associated with
familial forms of PD [122].
TgM83+/− rapidly developed signs of synucleinopathy
and widespread deposition of LBs upon intracerebral in-
oculation of brain extracts from MSA cases. However, fi-
brils extracted from TgM83+/+ (homozygous for the
mutation, naturally developing α-synuclein aggregates)
were not able to passage the pathology when injected in
TgM83+/− mice. The same group reported in a follow up
study [123] that fibrils derived from brain homogenates
derived from PD patients were not able to trigger the
pathology when injected into hemizygous mice or in HEK
cells owing the same A53T mutation, similarly to what
could be observed with fibrils derived from TgM83+/+
mice. These results indicated that different strains of α-
synuclein underlie the clinical manifestations of PD and
MSA.
Moreover, brain homogenates derived from DLB and
MSA patients also differed in their seeding activity when
injected into wild-type mice [113]. In addition, MSA de-
rived α-synuclein is more aggressive than PD/DLB,
which may depend on the conformation of the misfolded
seed (more compact structure) as well as from the intra-
cellular environment [115]. MSA- and PD/DLB α-
synuclein have no cell type preference in seeding α-
synuclein pathology, even though they showed a different
cell type distribution in MSA and DLB. In transmission
studies (carried out in TgM83+/− mice that were hemi-
zygous for the human α-synuclein A53T transgene) with
MSA α-synuclein there is a predominance of neuronal
over oligodendroglial inclusions, which might be a
Table 2 Comparison of different α-synuclein RT-QuIC protocols. The table summarizes the differences in the protocols so far
developed to detect α-synuclein seeding activity in the RT-QuIC. In Fairfoul et al., * 42 DLB samples included 12 pure DLB, 17 DLB +
AD and 13 AD with incidental Lewy bodies. ** Not determined. *** In Kang et al., T50 (time to reach 50% of the maximum of
fluorescence) was calculated as function of the unified Parkinson disease rating scale (UPDRS) instead of the lag time. T50 was
approximately 50 h. **** Due to the limited number of samples analysed, De Luca et al. decided both to calculate specificity and
sensitivity. Extracting these data from the paper resulted in specificity of 65.5% and sensitivity 84.3% for OM seeded reactions
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consequence of the “artificial environment” not reflect-
ing the conditions in MSA patients. In this context it
was reported that the cellular milieu in oligodendrocytes
is responsible for the transformation of misfolded α-
synuclein into a MSA strain [115], while seeding activity
of MSA-α-synuclein is maintained when propagated in
neurons, which shows that the strain characteristics de-
pend also on the conformation of the misfolded seed
[115].
The first evidence of the ability of α-synuclein aggregates
to produce different strains was performed by incubating
monomeric α-synuclein in different salt concentrations
[124].
High salt (termed buffer A) resulted in the formation of
assemblies within hours, whereas low salt buffer (buffer B)
had a longer lag phase before aggregation. Aggregate for-
mation from buffer A was reversible (they depolymerize
by incubation at 4 °C and re-polymerize upon heating at
37 °C). In contrast, aggregates formed in buffer B were
irreversible.
Electron microscope analysis revealed differences in
the structure of these aggregates. Assemblies from buffer
A showed a cylindrical aspect, while aggregates derived
from buffer B had a planar and often twisted structure.
Due to their appearances, buffer A aggregates were
termed fibrils and buffer B assemblies were termed rib-
bons. These two species were shown to further differ for
their PK banding profile. Different PK profiles are gener-
ated due to different cleavage sites of the PK, which may
depend on the conformation of misfolded α-synuclein.
Indeed, ribbons could not bind to Th-T, whereas fibrils
did. The structure of these aggregates also differs, with
ribbons owing a rigid and β-sheet enriched N-terminal
moiety, whereas the N-terminal part of the fibrils ap-
pears to be mostly disordered [124]. The two strains
were further distinguished by their toxicity upon admin-
istration into human neuroblastoma SH-SY5Y cell cul-
tures, with ribbons causing a less extensive cell deaths
compared to fibrils. In a following study [114], fibrils
and ribbons were reported to bear pathogenic potential
when injected in the substantia nigra of rats, with fibrils
exhibiting the highest toxic effect compared to oligomers
or ribbons, indicating that strains can be further differ-
entiated by their cytotoxic effects. Lastly, serial sonic-
ation steps were reported to produce a synthetic α-
synuclein strain which displays less ability in seeding the
aggregation of α-synuclein in neuronal cultures com-
pared to PFFs. However, this strain had a greater ability
of seeding tau aggregation in vitro [86] but only a minor
effect on tau aggregation in transgenic mice. The pres-
ence of lipopolysaccharides was further reported to pro-
duce different conformations of α-synuclein fibrils [125].
Although α-synuclein oligomers are considered as the
main reactive species for the onset of neurodegeneration
[21], there are evidences of stabilized protofibrils that are
unable to form mature fibrils. These species are termed
off-pathway oligomers, as they result in stable oligomers
lacking in seeding activity [126]. Various types of off-
pathway oligomers have been generated in vitro by the
addition of molecules that allow the formation of kinetic-
ally stable molecules unable to further aggregate into fi-
brils. Several molecules have been shown to favour the
formation of off-pathway oligomers. By varying the salt-,
buffer- and pH environmental conditions, Pham and co-
workers [127] showed that different dopamine redox
products display various effects on in vitro α-synuclein ag-
gregation. Specifically, whereas under acidic conditions
dopamine is stable and inhibits the oligomerization, higher
pH values cause the formation of redox catabolites of
dopamine, which promote the formation of soluble, SDS-
resistant, off-pathway oligomers. However, the same redox
product, 5,6-dihydroxyindole, induces the formation of
on-pathway oligomers under acidic conditions generating
fibrils that are Th-T insensitive.
Peroxidation-derived reactive aldehydes, such as 4-
oxo-2-nonenal (ONE), have been shown to produce off-
pathway oligomers as well [128]. However, these α-
synuclein oligomers exhibit a beta-sheet structure and
appear to be able to induce the formation of fibrils with
a reduced rate of fibrillation.
Lastly, α-synuclein off-pathway oligomers may be gener-
ated by the presence of the polyphenol epigallocatechin
gallate (EGCG [129]), a potent inhibitor of the in vitro ag-
gregation of huntingtin and α-synuclein.
The scheme for the aggregation pathway of natively un-
folded proteins (Fig. 2A) may therefore be implemented (as
shown in Fig. 2B) by taking into account the environmental
factors and the production of a population of strains, whose
constraints are dependent on the minimization of the free
energy of the conformer and ultimately converge into a lim-
ited variety of fibrillary structures or off-pathway species
(Fig. 2B) (in case of α-synuclein, fibrils, ribbons and
amorphous aggregates [19, 40]).
Conclusions
Since the introduction of the concept of self-propagating
proteins as common feature in neurodegenerative dis-
eases, whether different conformations, or strains of
pathogenic proteinaceous material might underlie simi-
lar diseases has been a long lasting conundrum. As
strains may emerge from light variations in the reaction
micro-environment and from the binding to different
partners, an in-depth characterization of both the reac-
tion conditions and the presence of biomolecules appear
to be necessary. Here we extend the classical view of
protein aggregation to include strain variability and
micro-environmental factors that may aid to understand
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the heterogeneity of conformational variants of a na-
tively unfolded protein such as α-synuclein.
“Pure” α-synucleinopathies strikingly differ for their
clinical manifestation, route of spreading and prodromic
phase of the disease. As the technology of in vitro, cell-
free systems, such as the RT-QuIC, progresses, subtle
differences of the misfolded species of proteins that may
contribute to neurodegenerative diseases are starting to
manifest, indicating that strain-typing might be a rele-
vant factor behind the clinical course of similar, albeit
different diseases, as in the case of PD and DLB.
Here, we attempted to comprehensively review the com-
plex landscape that regulates the folding and aggregation
of α-synuclein, scouring through the intrinsic (i.e., muta-
tions associated with pathology and PTMs) and extrinsic
(micro-environmental) factors that influence the topology
of α-synuclein both in pathology and physiology. These
factors need to be taken into account in order to develop
reliable assays for the diagnosis of α-synucleinopathies.
Indeed, to establish the α-synuclein RT-QuIC in the
diagnostic of α-synucleinopathies (pre-mortem in CSF
or post-mortem in brain) the following standardization
steps will be required: 1) Pre-analytical sample treat-
ments (type of storage tube), 2) harmonization of test-
protocols (composition of the reaction mix, kind of α-
synuclein substrate, incubation times and shaking etc.),
3) definition of a positive reaction, 4) determination of
stability of the misfolded α-synuclein seed against stor-
age conditions, and 5) investigation of the tolerance of
the RT-QuIC against blood contamination.
Abbreviations
DLB: Dementia with lewy body; FC: Frontal cortex; GAG: Glycosaminoglycan
chains; IDPs: Intrinsically disordered proteins; Lewy body dementia; LBs: Lewy
bodies; MSA: Multiple system atrophy; PD: Parkinson’s disease; PFF: Pre-
Figure 2 Proposed models for the aggregation pathway. a Established schematic view for the pathway of aggregation of natively unfolded
proteins [40]. According to this model, from an unfolded protein (UN) is formed an intermediate (I), which further aggregates into protofibrils (P)
and eventually into fibrils (F). b The extended model we propose takes into account the possibility that a population of strains are produced,
together with off-pathway oligomers that do not show the ability to form α-synuclein fibrils. Intermediate forms marked as I1 to In, each of
them may produce a different protofibrillar form, marked as P1-n to Pn-n (the protofibril P1 derived from the intermediate I1 until the protofibril Pn
derived from the intermediate In). It is noteworthy to state that the process may be in equilibrium between the aggregation of the intermediates
and the rupture of protofibrillar forms. Further aggregation will cause the collapse into a limited number of fibrillar structures
Candelise et al. Translational Neurodegeneration             (2020) 9:5 Page 12 of 16
formed fibril; PK: Proteinase K; PrPC: Cellular prion protein; PrPSc: Scrapie prion
protein; PTMs: Posttranslationale modifications; REM: Rapid eye movement;
rfu: Relative fluorescence units; RT-QuIC: Real-time quaking-induced conver-
sion; SNc: Substantia nigra pars compacta; Th-T: Thioflavin-T
Authors’ contributions
Concept and design: NC, MS, IZ; Writing: NC, MS, IZ; Drafting the review: AR,
ES, HV, KT, MC, SZ, AVP, FL. All authors read and approved the final
manuscript.
Funding
The project was supported by the German Academic Exchange Service
(DAAD) project 57421248, by the Alzheimer Forschung Initiative (AFI) project
17022 and the Instituto Carlos III (Miguel Servet programme—CP16/00041)
to FL).
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.





The authors declare that they have no competing interests.
Author details
1Department of Neurology, University Medicine Goettingen and the German
Center for Neurodegenerative Diseases (DZNE), Robert-Koch -Straße 40,
37075 Göttingen, Germany. 2Biomedical Engineering and Sciences
Department, School of Mechanical and Manufacturing Engineering (SMME),
National University of Sciences and Technology (NUST), Islamabad, Pakistan.
3Department of Experimental, Diagnostic and Speciality Medicine, University
of Bologna, Bologna, Italy. 4Departamento de Neuropatología y Banco de
Tejidos (BT-CIEN), Fundación CIEN, Instituto de Salud Carlos III Centro
Alzheimer Fundación Reina Sofíac, Valderrebollo n° 5, 28031 Madrid, Spain.
5ADx NeuroSciences, Technologiepark 4, Ghent, Belgium. 6CIBERNED
(Network center for biomedical research of neurodegenerative diseases),
Institute Carlos III, Madrid, Spain. 7Bellvitge Biomedical Research Institute
(IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
Received: 4 September 2019 Accepted: 23 December 2019
References
1. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying
clinical variability in patients with synucleinopathies. Acta Neuropathol.
2011;122:187–204.
2. Schönfelder J, Alonso-Caballero A, De Sancho D, Perez-Jimenez R. The life of
proteins under mechanical force. Chem Soc Rev. 2018;47(10):3558–73.
3. Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and
quality control. Science. 2016;353(6294):acc4354.
4. Eisenberg D, Jucker M. The amyloid state of proteins in human diseases.
Cell. 2012;148(6):1188–203.
5. Oldfield CJ, Dunkler AK. Intrinsically disordered proteins and intrinsically
disordered protein regions. Ann Rev Biochem. 2014;83:553-84.
6. Carrell RW, Gooptu B. Conformational changes and disease—Serpins, prions
and Alzheimer’s. Curr Opin Struct Biol. 1998;8(6):799–809.
7. Frantzmann T, Alberti S. Prion-like low-complexity sequences: key regulators
of protein solubility and phase behavior. J Biol Chem. 2018;294(18):7128-36.
8. Dobson CM. Protein misfolding, evolution and disease. Trends Biochem Sci.
1999;24(9):329–32.
9. Skrabana R, Sevcik J, Novak M. Intrinsically disordered proteins in the
neurodegenerative processes: formation of tau protein paired helical
filaments and their analysis. Cell Mol Neurobiol. 2006;26(7–8):1085–97.
10. Uversky VN, Oldfield CJ, Midic U, Xie H, Xue B, Vucetic S, Iakoucheva LM,
Obradovic Z, Dunker AK. Unfoldomics of human diseases: linking protein
intrinsic disorder with diseases. BMC Genomics. 2006;10 Suppl 1:S7.
11. Levine ZA, Larini L, LaPointe NE, Feinstein SC, Shea JE. Regulation and
aggregation of intrinsically disordered peptides. Proc Natl Acad Sci U S A.
2015;112(9):2758–63.
12. Kirschner DA, Abraham C, Selkoe DJ. X-ray diffraction from intraneuronal
paired helical filaments and extraneuronal amyloid fibers in Alzheimer
disease indicates cross-beta conformation. Proc Natl Acad Sci U S A. 1986;
83(2):503–7.
13. Kisilevsky R, Raimondi S, Bellotti V. Historical and current concepts of
Fibrillogenesis and in vivo Amyloidogenesis: implications of amyloid tissue
targeting. Front Mol Biosci. 2016;3:17.
14. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS
Lett. 2001;498(2–3):204–7.
15. Soto C. Unfolding protein misfolding in neurodegenerative diseases. Nat
Rev Neurosci. 2003;4(1):49–60.
16. Prusiner SB. Prions: novel infectious pathogens. Adv Virus Res. 1984;29:1–56.
17. Prusiner SB. Biology and genetics of prion diseases. Annu Rev Microbiol.
1994;48:655–86.
18. Goedert M, Jakes R, Spillantini MG. The Synucleinopathies: twenty years on.
J Park Dis. 2017;7(s1):S51–69.
19. Peelaerts W, Baekelandt V. ɑ-Synuclein strains and the variable pathologies
of synucleinopathies. J Neurochem. 2016;139(Suppl. 1):256–74.
20. Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and
neurotoxicity of recombinant α-synuclein aggregates initiated by
dimerization. Mol Neurodegener. 2013;8:5.
21. Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-
synuclein oligomers: a new hope. Acta Neuropathol. 2017;134(6):819–38.
22. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf
MF, Lindquist SL. Nucleated conformational conversion and the replication
of conformational information by a prion determinant. Science. 2000;
289(5483):317–1321.
23. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like
pathology in long-term embryonic nigral transplants in Parkinson's disease.
Nat Med. 2008;14(5):504–6.
24. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted
dopaminergic neurons develop PD pathologic changes: a second case
report. Mov Disord. 2008;23(16):2303–6.
25. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP,
Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy
bodies in grafted neurons in subjects with Parkinson's disease suggest host-
to-graft disease propagation. Nat Med. 2008;14(5):501–3.
26. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ,
Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-
synuclein release and transmission. Neurobiol Dis. 2011;42(3):360–7.
27. Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC. Induction of neuronal
cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol
Chem. 2001;276(29):27441–8.
28. Eichmann C, Kumari P, Riek R. High-density lipoprotein-like particle
formation of Synuclein variants. FEBS Lett. 2017;591(2):304–11.
29. Lööv C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M. α-Synuclein in
extracellular vesicles: functional implications and diagnostic opportunities.
Cell Mol Neurobiol. 2016;36(3):437–8.
30. Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D,
Adame A, Masliah E, Rissman RA. Brain-derived exosomes from dementia
with Lewy bodies propagate α-synuclein pathology. Acta Neuropathol
Commun. 2017;5(1):46.
31. Luk KC, Covell DJ, Kehm VM, Zhang B, Song IY, Byrne MD, Pitkin RM, Decker
SC, Trojanowski JQ, Lee VM. Molecular and biological compatibility with host
alpha-synuclein influences fibril pathogenicity. Cell Rep. 2016;16(12):3373–87.
32. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M,
Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of α-
synuclein fibrils through axonal transport. Ann Neurol. 2012;72(4):517–24.
33. Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM,
Brundin P. Widespread transneuronal propagation of α-synucleinopathy
triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp
Med. 2016;213(9):1759–78.
34. Ulusoy A, Rusconi R, Pérez-Revuelta BI, Musgrove RE, Helwig M, Winzen-
Reichert B, Di Monte DA. Caudo-rostral brain spreading of α-synuclein
through vagal connections. EMBO Mol Med. 2013;5(7):1119–27.
35. Naiki H, Nagai H. Molecular pathogenesis of protein misfolding diseases:
pathological molecular environments versus quality control systems against
misfolded proteins. J Biochem. 2009;146(6):751–6.
Candelise et al. Translational Neurodegeneration             (2020) 9:5 Page 13 of 16
36. Coskuner O, Wise-Scira O. Structures and free energy landscapes of the
A53T mutant-type α-synuclein protein and impact of A53T mutation on the
structures of the wild-type α-synuclein protein with dynamics. ACS Chem
Neurosci. 2013;4(7):1101–13.
37. Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TP, Linse
S, Dobson CM. Solution conditions determine the relative importance of
nucleation and growth processes in α-synuclein aggregation. Proc Natl
Acad Sci U S A. 2014;111(21):7671–6.
38. Grey M, Linse S, Nilsson H, Brundin P, Sparr E. Membrane interaction of
alpha-synuclein in different aggregation states. J Park Dis. 2011;1(4):359–71.
39. Naiki H, Yamamoto S, Hasegawa K, Yamaguchi I, Goto Y, Gejyo F. Molecular
interactions in the formation and deposition of beta2-microglobulin-related
amyloid fibrils; 2005.
40. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations,
aggregation, and fibrillation of human alpha-synuclein. A possible molecular
NK between Parkinson's disease and heavy metal exposure. J Biol Chem.
2001;276(47):44284–96.
41. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Phys. 1982;
243(5):C212–21.
42. Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, Subramaniam V. Cellular
spermidine promote the aggregation of alpha-synuclein. J Biol Chem. 2003;
278(5):3235–40.
43. Lewandowski NM, Ju S, Verbitsky M, Ross B, Geddie ML, Rockenstein E,
Adame A, Muhammad A, Vonsattel JP, Ringe D, Cote L, Lindquist S, Masliah
E, Petsko GA, Marder K, Clark LN, Small SA. Polyamine pathway contributes
to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A. 2010;
107(39):16970–5.
44. Krasnoslobodtsev AV, Peng J, Asiago JM, Hindupur J, Rochet JC,
Lyubchenko YL. Effect of spermidine on misfolding and interactions of
alpha-synuclein. PLoS One. 2012;7(5):e38099.
45. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO,
Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D,
Diamond MI. Heparan sulfate proteoglycans mediate internalization and
propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;
110(33):E3138–47.
46. Ihse E, Yamakado H, van Wijk XM, Lawrence R, Esko JD, Masliah E. Cellular
internalization of alpha-synuclein aggregates by cell surface heparan sulfate
depends on aggregate conformation and cell type. Sci Rep. 2017;7(1):9008.
47. Cohlberg JA, Li J, Uversky VN, Fink AL. Heparin and other
glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-
synuclein in vitro. Biochemistry. 2002;41(5):1502–11.
48. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein:
from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;
14(1):38–48.
49. Perry G, Richey P, Siedlak SL, Galloway P, Kawai M, Cras P. Basic fibroblast
growth factor binds to filamentous inclusions of neurodegenerative
diseases. Brain Res. 1992;579(2):350–2.
50. Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ. Agrin binds
alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology.
2005;15(12):1320–31.
51. Liu C, Zhang Y. Nucleic acid-mediated protein aggregation and assembly.
Acta Protein ChemStruct Biol. 2011;84:1–40.
52. Cordeiro Y, Silva JL. The hypothesis of the catalytic action of nuclei acid on
the conversion of prion protein. Protein Pept Lett. 2005;12:251–5.
53. Yin J, Chen R, Liu C. Nucleic acid induced protein aggregation and its role
in biology and pathology. Front Biosci (Landmark Ed). 2009;14:5084–106.
54. Cordeiro Y, Macedo B, Silva JL, Gomes MPB. Pathological implications of
nucleic acid interactions with proteins associated with neurodegenerative
diseases. Biophys Rev. 2014;6(1):97–110.
55. Hegde ML, Rao KS. DNA induces folding in alpha-synuclein: understanding
the mechanism using chaperone property of osmolytes. Arch Biochem
Biophys. 2007;464(1):57–69.
56. Fricker M, Tolkovsky AM, Borutaite V, Coleman M, Brown GC. Neuronal Cell
Death. Physiol Rev. 2018;98(2):813–80.
57. Liu C, Fang Y. New insights of poly (ADP-ribosylation) in neurodegenerative
diseases: a focus on protein phase separation and pathologic aggregation.
Biochem Pharmacol. 2019. https://doi.org/10.1016/j.bcp.2019.04.028.
58. Donyo M, Ashkenazi A. The cell-death-associated polymer PAR feeds
forward α-synuclein toxicity in Parkinson's disease. Mol Cell. 2019;73(1):5–6.
59. Kam TI, Mao X, Park H, Chou SC, Karuppagounder SS, Umanah GE, Yun SP,
Brahmachari S, Panicker N, Chen R, Andrabi SA, Qi C, Poirier GG, Pletnikova
O, Troncoso JC, Bekris LM, Leverenz JB, Pantelyat A, Ko HS, Rosenthal LS,
Dawson TM, Dawson VL. Poly (ADP-ribose) drives pathologic α-synuclein
neurodegeneration in Parkinson's disease. Science. 2018;362(6414). https://
doi.org/10.1126/science.aat8407.
60. Gorobenko GP, Kinnunen KJ. The role of lipid-protein interactions in
amyloid-type protein fibril formation. Chem Phys Lipids. 2006;141(1–2):72–
82.
61. Uverski LN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded
conformation during alpha-synuclein oligomerization in both purified and
cytosolic preparations. J Biol Chem. 2001;276(47):43495–8.
62. Perrin RJ, Woods WS, Clayton DF, George JM. Exposure to long chain
polyunsaturated fatty acids triggers rapid multimerization of synucleins. J
Biol Chem. 2001;276(45):41958–62.
63. Perrin RJ, Woods WS, Clayton DF, George JM. Interaction of human alpha-
synuclein and Parkinson's disease variants with phospholipids. Structural
analysis using site-directed mutagenesis. J Biol Chem. 2000;275(44):34393–8.
64. Brummel BE, Braun AR, Sachs JN. Polyunsaturated chains in asymmetric
lipids disorder raft mixtures and preferentially associate with α-synuclein.
Biochim Biophys Acta Biomembr. 2017;1859(4):529–36.
65. Fecchio C, Palazzi L, de Laureto PP. α-Synuclein and polyunsaturated fatty
acids: molecular basis of the interaction and implication in
neurodegeneration. Molecules. 2018;23(7).
66. Galvagnion C, Brown JW, Ouberai MM, Flagmeier P, Vendruscolo M, Buell
AK, Sparr E, Dobson CM. Chemical properties of lipids strongly affect the
kinetics of the membrane-induced aggregation of α-synuclein. Proc Natl
Acad Sci U S A. 2016;13(26):7065–70.
67. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM,
Trojanowski JQ, Mann D, Iwatsubo T. Phosphorylated alpha-synuclein is
ubiquitinated in alpha-synucleinopathy lesions. Biol Chem. 2002;277(50):
49071–6.
68. Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Muñoz L,
Querol-Vilaseca M, Martín-Paniello CS, Luque-Cabecerans J, Clarimon J,
Belbin O, Núñez-Llaves R, Blesa R, Smith C, McKenzie CA, Frosch MP, Roe A,
Fortea J, Andilla J, Loza-Alvarez P, Gelpi E, Hyman BT, Spires-Jones TL, Lleó
A. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies.
Brain. 2017;140(12):3204–14.
69. Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein post-
translational modifications as potential biomarkers for Parkinson disease and
other synucleinopathies. Mol Cell Proteomics. 2013;12(12):3543–58.
70. Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R, Ferrer I. Evidence
of oxidative stress in the neocortex in incidental Lewy body disease. J
Neuropathol Exp Neurol. 2005;64(9):816–30.
71. Gomez A, Ferrer I. Involvement of the cerebral cortex in Parkinson disease
linked with G2019S LRRK2 mutation without cognitive impairment. Acta
Neuropathol. 2010;120(2):155–67.
72. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro
cross-linking of alpha-synuclein and accelerate the process of intracellular
inclusion body formation. J Neurosci Res. 2008;86(9):2071–82.
73. Vicente Miranda H, Cássio R, Correia-Guedes L, Gomes MA, Chegão A,
Miranda E, Soares T, Coelho M, Rosa MM, Ferreira JJ, Outeiro TF.
Posttranslational modifications of blood-derived alpha-synuclein as
biochemical markers for Parkinson's disease. Sci Rep. 2017;7(1):13713.
74. Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of α-
synuclein in neurodegeneration of Parkinson's disease: a review of in vivo
models. Rev Neurosci. 2013;24(2):115–23.
75. Arawaka S, Sato H, Sasaki A, Koyama S, Kato T. Mechanisms underlying
extensive Ser129-phosphorylation in α-synuclein aggregates. Acta
Neuropathol Commun. 2017;5(1):48. https://doi.org/10.1186/s40478-017-
0452-6.
76. Hwang CS, Shemorry A, Varshavsky A. N-terminal acetylation of cellular
proteins creates specific degradation signals. Science. 2010;327:973–7.
77. Dikiy I, Eliezer D. N-terminal acetylation stabilizes N-terminal Helicity in lipid-
and micelle-bound α-Synuclein and increases its affinity for physiological
membranes. J Biol Chem. 2014;289(6):3652–5.
78. Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J,
Giasson BI. Physiological C-terminal truncation of α-synuclein potentiates
the prion-like formation of pathological inclusions. J Biol Chem. 2018;
293(49):18914–32.
79. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM,
Jäkälä P, Hartmann T, Price DL, Lee MK. Aggregation promoting C-terminal
truncation of α-synuclein is a normal cellular process and is enhanced by
Candelise et al. Translational Neurodegeneration             (2020) 9:5 Page 14 of 16
the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A.
2005;102:2162–7.
80. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H,
Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by
selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;
290(5493):985–9.
81. Burai R, Ait-Bouziad N, Chiki A, Lashuel HA. Elucidating the role of site-
specific nitration of α-synuclein in the pathogenesis of Parkinson's disease
via protein semisynthesis and mutagenesis. J Am Chem Soc. 2015;137(15):
5041–52.
82. Engelender S. Ubiquitination of alpha-synuclein and autophagy in
Parkinson's disease. Autophagy. 2008;4(3):372–4.
83. Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, Savitt JM.
Development and characterization of a new Parkinson's disease model
resulting from impaired autophagy. J Neurosci. 2012;32(46):16503–9.
84. Rott R, Szargel R, Shani V, Hamza H, Savyon M, Abd Elghani F,
Bandopadhyay R, Engelender S. SUMOylation and ubiquitination reciprocally
regulate α-synuclein degradation and pathological aggregation. Proc Natl
Acad Sci U S A. 2017;144(50):13176–81.
85. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, Bossis G, Urlaub H,
Zweckstetter M, Kügler S, Melchior F, Bähr M, Weishaupt JH. Sumoylation
inhibits alpha-synuclein aggregation and toxicity. J Cell Biol. 2011;194(1):49–60.
86. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong
LK, Xu Y, Trojanowski JQ, Lee VM. Distinct α-synuclein strains differentially
promote tau inclusions in neurons. Cell. 2013;154(1):103–17.
87. Katorcha E, Makarava N, Lee YJ, Lindberg I, Monteiro MJ, Kovacs GG,
Baskakov IV. Cross-seeding of prions by aggregated α-synuclein leads to
transmissible spongiform encephalopathy. PLoS Pathog. 2017;13(8):
e1006563.
88. Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM,
Froula J, Duffy MF, Lee VMY, Martinez TN, Dave KD. Best practices for
generating and using alpha-synuclein pre-formed fibrils to model
Parkinson's disease in rodents. J Park Dis. 2018;8(2):303–22.
89. Luna E, Decker SC, Riddle DM, Caputo A, Zhang B, Cole T, Caswell C, Xie SX,
Lee VMY, Luk KC. Differential α-synuclein expression contributes to selective
vulnerability of hippocampal neuron subpopulations to fibril-induced
toxicity. Acta Neuropathol. 2018;135(6):855–75.
90. Villar-Piqué A, Schmitz M, Candelise N, Ventura S, Llorens F, Zerr I. Molecular
and clinical aspects of protein aggregation assays in neurodegenerative
diseases. Mol Neurobiol. 2018;55(9):7588–605.
91. Come JH, Fraser PE, Lansbury PT Jr. A kinetic model for amyloid formation
in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A.
1993;90(13):5959–63.
92. Schmitz M, Cramm M, Llorens F, Müller-Cramm D, Collins S, Atarashi R,
Satoh K, Orrú CD, Groveman BR, Zafar S, Schulz-Schaeffer WJ, Caughey B,
Zerr I. The real-time quaking-induced conversion assay for detection of
human prion disease and study of other protein misfolding diseases. Nat
Protoc. 2016;11(11):2233–42.
93. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein
by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810–3.
94. Castilla J, Saá P, Hetz C, Soto C. In vitro generation of infectious scrapie
prions. Cell. 2005;12(2):195–206.
95. Saá P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by
automated protein misfolding cyclic amplification. J Biol Chem. 2006;
281(46):35245–52.
96. Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho MV, Soto C. Protein
misfolding cyclic amplification of infectious prions. Nat Protoc. 2012;7(7):1397–409.
97. Castilla J, Saá P, Soto C. Detection of prions in blood. Nat Med. 2005;11(9):
982–5.
98. Murayama Y, Yoshioka M, Okada H, Takata M, Yokoyama T, Mohri S. Urinary
excretion and blood level of prions in scrapie-infected hamsters. J Gen Virol.
2007;88(pt. 10):2890–8.
99. Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C,
Mollenhauer B, Soto C. Development of a biochemical diagnosis of
Parkinson disease by detection of α-Synuclein Misfolded aggregates in
cerebrospinal fluid. JAMA Neurol. 2017;74(2):163–72.
100. Colby DW, Zhang Q, Wang S, Groth D, Legname G, Riesner D, Prusiner SB.
Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A.
2007;104(52):20914–9.
101. Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM,
Onwubiko HA, Priola SA, Caughey B. Simplified ultrasensitive prion
detection by recombinant PrP conversion with shaking. Nat Methods. 2008;
5(3):211–2.
102. Orrú CD, Wilham JM, Hughson AG, Raymond LD, McNally KL, Bossers A,
Ligios C, Caughey B. Human variant Creutzfeldt-Jakob disease and sheep
scrapie PrP (res) detection using seeded conversion of recombinant prion
protein. Protein Eng Des Sel. 2009;22(8):515–21.
103. Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of prion propagation:
amyloid growth occurs by monomer addition. PLoS Biol. 2004;2(10):e321.
104. Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C,
Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT,
Parkkinen L, Green AJ. Alpha-synuclein RT-QuIC in the CSF of patients with
alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–8.
105. Sano K, Atarashi R, Satoh K, Ishibashi D, Nakagaki T, Iwasaki Y, Yoshida M,
Murayama S, Mishima K, Nishida N. Prion-like seeding of Misfolded α-
Synuclein in the brains of dementia with Lewy body patients in RT-QUIC.
Mol Neurobiol. 2018;55(5):3916–30.
106. Groveman BR, Orrù CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B,
Campbell KJ, Safar J, Galasko D, Caughey B. Rapid and ultra-sensitive
quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal
fluid by αSyn RT-QuIC. Acta Neuropathol Commun. 2018;6(1):7.
107. Manne S, Kondru N, Hepker M, Jin H, Anantharam V, Lewis M, Huang X,
Kanthasamy A, Kanthasamy AG. Ultrasensitive detection of aggregated α-
Synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the
RT-QuIC assay: new high-throughput Neuroimmune biomarker assay for
Parkinsonian disorders. J NeuroImmune Pharmacol. 2019. https://doi.org/10.
1007/s11481-019-09835-4.
108. Candelise N, Schmitz M, Llorens F, Villar-Piqué A, Cramm M, Thom T, da
Silva Correia SM, da Cunha JEG, Möbius W, Outeiro TF, Álvarez VG, Banchelli
M, D'Andrea C, de Angelis M, Zafar S, Rabano A, Matteini P, Zerr I. Seeding
variability of different alpha synuclein strains in synucleinopathies. Ann
Neurol. 2019;85(5):691–703.
109. Garrido A, Fairfoul G, Tolosa ES, Martí MJ, Green A, Barcelona LRRK2 Study
Group. α-Synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked
Parkinson's disease. Ann Clin Transl Neurol. 2019;6(6):1024–32.
110. van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM.
α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid
of uncertain cases of parkinsonism. Ann Neurol. 2019;85(5):777–81.
111. Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, Green A,
Soto C. Comparative study of cerebrospinal fluid α-synuclein seeding
aggregation assays for diagnosis of Parkinson's disease. Mov Disord. 2019;
34(4):536–44.
112. De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E, De
Cecco E, Narkiewicz J, Salzano G, Carletta O, Romito L, Devigili G, Soliveri P,
Tiraboschi P, Legname G, Tagliavini F, Eleopra R, Giaccone G, Moda F.
Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa
samples of patients with Parkinson's disease and multiple system atrophy.
Transl Neurodegener. 2019;8:24.
113. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM,
DeArmond SJ, Prusiner SB. Transmission of multiple system atrophy prions
to transgenic mice. Proc Natl Acad Sci U S A. 2013;110(46):19555–60.
114. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano
M, Van den Haute C, Melki R, Baekelandt V. α-Synuclein strains cause
distinct synucleinopathies after local and systemic administration. Nature.
2015;552(7556):430–344.
115. Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, Zhang
B, Pitkin RM, Olufemi MF, Luk KC, Trojanowski JQ, Lee VM. Cellular milieu
imparts distinct pathological α-synuclein strains in α-synucleinopathies.
Nature. 2018;557(7706):558–63.
116. Wemheuer WM, Wrede A, Schulz-Schaeffer WJ. Types and strains: their
essential role in understanding protein aggregation in neurodegenerative
diseases. Front Aging Neurosci. 2017;9:187.
117. Cuillé J, Chell PL. La maladie dite tramblante du mouton est-ell inoculable?
C.R. Acad Sci. 1936;208:1552–4.
118. Pattison IH, Millson GC. Scrapie produced experimentally in goats with
special reference to the clinical syndrome. J Comp Pathol. 1961;71:101–9.
119. Bessen RA, Kocisko DA, Raymond GJ, Nandan S, Lansbury P, Caughey B.
Non-genetic propagation of strain-specific properties of scrapie prion
protein. Nature. 1995;475(6533):698–700.
120. Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB.
Eight prion strains have PrP (Sc) molecules with different conformations.
Nat Med. 1998;4(10):1157–65.
Candelise et al. Translational Neurodegeneration             (2020) 9:5 Page 15 of 16
121. Thakur P, Breger LS, Lundblad M, Wan OW, Mattsson B, Luk KC, Lee VMY,
Trojanowski JQ, Björklund A. Modeling Parkinson's disease pathology by
combination of fibril seeds and α-synuclein overexpression in the rat brain.
Proc Natl Acad Sci U S A. 2017;114(39):E8284–93.
122. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal
alpha-synucleinopathy with severe movement disorder in mice expressing
A53T human alpha-synuclein. Neuron. 2002;34(4):521–33.
123. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB,
Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday
GM, Middleton LT, Gentleman SM, Grinberg LT, Giles K. Evidence for α-
synuclein prions causing multiple system atrophy in humans with
parkinsonism. Proc Natl Acad Sci U S A. 2015;112(38):E5308–17.
124. Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona
K, Olieric V, Böckmann A, Meier BH, Melki R. Structural and functional
characterization of two alpha-synuclein strains. Nat Commun. 2013;4:2575.
125. Kim C, Lv G, Lee JS, Jung BC, Masuda-Suzukake M, Hong CS, Valera E, Lee
HJ, Paik SR, Hasegawa M, Masliah E, Eliezer D, Lee SJ. Exposure to bacterial
endotoxin generates a distinct strain of α-synuclein fibril. Sci Rep. 2016;6:
30891.
126. Fagerqvist T, Näsström T, Ihse E, Lindström V, Sahlin C, Tucker SM, Kasaryan
A, Karlsson M, Nikolajeff F, Schell H, Outeiro TF, Kahle PJ, Lannfelt L,
Ingelsson M, Bergström J. Off-pathway α-synuclein oligomers seem to alter
α-synuclein turnover in a cell model but lack seeding capability in vivo.
Amyloid. 2013;20(4):233–44.
127. Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai
R. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole
promote distinct on-pathway and off-pathway aggregation of alpha-
synuclein in a pH-dependent manner. J Mol Biol. 2009;387(3):771–85.
128. Näsström T, Fagerqvist T, Barbu M, Karlsson M, Nikolajeff F, Kasrayan A,
Ekberg M, Lannfelt L, Ingelsson M, Bergström J. The lipid peroxidation
products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation
of α-synuclein oligomers with distinct biochemical, morphological, and
functional properties. Free Radic Biol Med. 2011;50(3):428–37.
129. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R,
Engemann S, Pastore A, Wanker EE. EGCG redirects amyloidogenic
polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol.
2008;15(6):558–66.
Candelise et al. Translational Neurodegeneration             (2020) 9:5 Page 16 of 16
